Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving nucleic acid
Reexamination Certificate
2005-10-24
2010-11-23
Goldberg, Jeanine A (Department: 1634)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving nucleic acid
C435S091100, C435S091200, C536S023100, C536S024300
Reexamination Certificate
active
07838229
ABSTRACT:
The present invention provides an identification marker responsive to IFN therapy for renal cell cancer and a means of detecting the same. Namely, a method which comprises preparing a genomic DNA of a human gene or a complementary strand thereof from a specimen of a patient with renal cell cancer, analyzing the DNA sequence of the genomic DNA or the complementary strand thereof to determine the gene polymorphism of the human gene, and evaluating the tumor-suppression effect of IFN therapy on renal cell cancer by using the polymorphism as an indicator.
REFERENCES:
patent: 2003/0096237 (2003-05-01), Certa
patent: 2004/0043379 (2004-03-01), Hashimoto et al.
patent: 2001-136973 (2001-05-01), None
patent: 2003-088382 (2003-03-01), None
patent: 2003-339380 (2003-12-01), None
patent: 2004-507253 (2004-05-01), None
patent: 2004033650 (2004-04-01), None
Shen et al. (BMC Cell Biology, vol. 3, 2002).
Hirschhorn et al. (Genetics in Medicine. vol. 4, No. 2, pp. 45-61, Mar. 2002).
Lucentini (The Scientist; 2004, vol. 24, p. 20.
Ioannidis (Nature Genetics, vol. 29, pp. 306-309, Nov. 2001).
Supplementary European Search Report in International Application No. PCT/JP2005/019491 dated Jun. 16, 2009.
Schlaak, J. F. et al., “Cell-type and donor specific transcriptional responses to interferon-alpha. Use of customized gene arrays”, J. Biol. Chem., 277 (51), p. 49428-37. Dec. 20, 2002.
Franzke, A. et al., “HLA phenotype an cytokine-induced tumor control in advanced renal cell cancer”, Cancer Biother Radiopharm, 16(5) p. 401-9, Oct. 2001.
Basturk, B. et al., “Cytokine gene polymorphisis as potential risk and protective factors in renal cell carcinoma”, Cytokine, 30(1), p. 41-5, Apr. 7, 2005.
Brookes, A. J. “The essence of SNPs”, Gene, 234, p. 177-186, 1999.
Cargill, M. et al., “Characterization of single-nucleotide polymorphisis in coding regions of human genes”, Nature Genet., 22, p. 231-238, 1999.
Evans, W. E. & Relling, M. V., “Pharmacogenomics: functional genomic into rational therapeutics”, Science, 286, P487-491, 1999.
Chinese Office Action issued Aug. 21, 2009, in CN 200580037257.3.
Genbank Accession No. ss14282437, published Nov. 5, 2003, retrieved from http://www.ncbi.nim.nih.gov/projects/SNP/snp—retrieve.cgi?subsnp—id=14282437.
Hirao Yoshihiko
Kagawa Susumu
Naito Seiji
Nakamura Tsuyoshi
Nose Yoshiaki
Goldberg Jeanine A
Otsuka Pharmaceutical Co. Ltd.
Sughrue & Mion, PLLC
LandOfFree
Identification marker responsive to interferon therapy for... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Identification marker responsive to interferon therapy for..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Identification marker responsive to interferon therapy for... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4184003